(Q67511185)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

editorial

0 references

title

Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

cost-effectiveness analysis

14 September 2019

main subject

1 reference

Drummond M

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

language of work or name

English

0 references

publication date

1 July 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

volume

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

page(s)

85-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

Cost-effectiveness and cost-benefit analyses in the medical literature. Are the methods being used correctly?

14 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Meta-analyses of randomized controlled trials.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Economic evaluation in health care: is there a role for cost-benefit analysis?

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Quality-adjusted life years, utility theory, and healthy-years equivalents

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

The use of QALYs in health care decision making

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Current practice in obtaining the "Q" in QALYs: a cautionary note

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Discounting and health benefits

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Economic evaluation of pharmaceuticals: science or marketing?

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Small-area variations in the use of common surgical procedures: an international comparison of New England, England, and Norway

1 reference

https://api.crossref.org/works/10.1002%2FHEC.4730010202

7 January 2021

Identifiers

DOI

10.1002/HEC.4730010202

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1341931%20AND%20SRC:MED&resulttype=core&format=json

14 September 2019

1 reference